GleamWall
中文EN

PLX Protalix BioTherapeutics, Inc.

Biological Products, (No Diagnostic Substances) · NYSE · SEC CIK 1006281 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY37.0%
TTM net income YoY281.0%
TTM EPS YoY200.0%
Revenue 3-yr CAGR10.0%
Net income 3-yr CAGR24.6%

Margins

Gross margin71.2%
Operating margin29.8%
Net margin24.3%
FCF margin17.8%
EBITDA margin31.7%

Returns

ROE30.8%
ROA20.5%
ROIC (approx.)41.0%
Asset turnover0.84x

Leverage & solvency

Liabilities / assets31.9%
Debt / equity0.00x
Current ratio3.27x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.85x
Accruals ratio3.0%
Payout ratio—
Capex / revenue2.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$21.93M$19.90M$33.75M$9.12M$17.85M$15.66M$10.11M$18.22M
Cost of revenue$7.88M$7.76M$4.13M$4.62M$8.32M$5.87M$8.18M$3.89M
Gross profit$14.05M$12.13M$29.62M$4.50M$9.53M$9.79M$1.93M$14.33M
R&D expense$6.92M$4.35M$5.43M$5.63M$4.47M$5.99M$3.48M$4.12M
SG&A expense$3.08M$3.11M$3.05M$3.53M$2.93M$2.62M$2.60M$3.00M
Operating income$4.05M$4.67M$21.15M-$4.66M$2.13M$1.17M-$4.14M$7.21M
Pretax income$4.62M$4.86M$21.14M-$4.78M$2.24M$661,000-$3.73M$7.32M
Income tax$661,000$1.08M$2.82M$728,000-$116,000$497,000-$113,000$822,000
Net income$3.96M$3.78M$18.32M-$5.50M$2.35M$164,000-$3.62M$6.49M
EBITDA$4.47M$5.08M$21.55M-$4.27M$2.50M$1.53M-$3.80M$7.54M
EPS (basic)0.050.050.23—0.030.00-0.05—
EPS (diluted)0.050.050.22—0.030.00-0.05—
Weighted avg. shares (diluted)83.59M82.56M83.05M—80.81M81.27M76.61M—
Balance sheet
Cash & equivalents$22.04M$27.42M$41.00M$14.68M$13.65M$17.89M$19.46M$19.76M
Receivables$13.91M$16.50M$2.94M$8.84M$14.43M$9.44M$4.67M$2.91M
Inventory$34.30M$32.29M$30.47M$25.73M$21.25M$21.13M$19.51M$21.24M
Current assets$98.87M$92.22M$86.36M$66.67M$66.50M$65.48M$60.51M$60.08M
PP&E, net$5.77M$5.47M$5.15M$4.88M$4.72M$4.75M$4.72M$4.59M
Total assets$118.24M$110.34M$102.34M$82.35M$82.26M$78.49M$73.89M$73.42M
Current liabilities$30.23M$31.39M$27.39M$26.52M$21.95M$24.09M$24.32M$25.62M
Total liabilities$37.69M$38.93M$35.11M$34.12M$29.36M$28.58M$28.68M$30.21M
Shareholders' equity$80.55M$71.40M$67.23M$48.23M$52.91M$49.90M$45.21M$43.21M
Shares outstanding———80.43M———75.85M
Cash flow statement
Operating cash flow$3.90M-$10.40M$22.02M$2.03M-$3.73M-$5.23M-$5.06M$3.99M
Capital expenditure$737,000$593,000$761,000$403,000$498,000$431,000$306,000$425,000
Free cash flow$3.17M-$10.99M$21.26M$1.63M-$4.23M-$5.66M-$5.36M$3.57M
Investing cash flow-$13.81M-$3.63M$4.22M-$1.11M-$504,000-$438,000-$312,000-$15.32M
Financing cash flow$4.58M$0$150,000$146,000$0$4.10M$5.08M$3.63M
Depreciation & amortization$421,000$406,000$404,000$387,000$372,000$360,000$346,000$334,000
Stock-based compensation$601,000$398,000$532,000$732,000$598,000$427,000$540,000$654,000

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.